**Appendix Table E12. Phenotypic test details in a single study assessing the predictive ability of LTA in patients with peripheral arterial disease**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Test/Device name**  **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement**  **Anticoagulant used**  **Interval between clopidogrel doses and blood sampling (in days)**  **Interval between sampling and testing (in days):** | **Grouping of Phenotypes**  **[Definition]** | **Rational for the grouping of phenotypes reported (Yes/No)**  **[short description]** | **Frequency of phenotypes** |
| Linnemann, 2010{Linnemann, 2010 82 /id}  20153859  Germany  NR | Light transmittance aggregometry  Behring Coagulation Timer (BCT)  Dade Behring, Düdingen, Switzerland | 2 umol/l ADP | venous blood  3.2% citrate  0.04-1 day (1-24 hrs); clopidogrel came first  0.04 – 0.125 days (1-3 hrs) | Non-responsiveness (late aggregation (LateAggr) ≥42.9%)  Responsiveness (late aggregation (LateAggr) <42.9%) | Based on guidelines (53rd Annual Scientific and Standardization Committee Meeting of the International Society of Thrombosis and Haemostasis, Geneva 2007) | Non-responsiveness (late aggregation (LateAggr) ≥42.9%): 19/34 (38.2%)  Responsiveness (late aggregation (LateAggr) <42.9%): 21/34 (61.8) |

\*If more than one test, they are presented in separate rows

ADP= adenosine 5'-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported.